South African pharmaceutical company Afrigen Biologics and Vaccines (Afrigen) expects a decision in mid-July 2021 on partners to produce Africa's first COVID-19 vaccine using mRNA technology, Reuters news agency reported on Thursday.
Reportedly, the World Health Organization selected Afrigen for a pilot to give poor and middle-income countries the know-how and licences to make COVID-19 vaccines. The "tech transfer hub" will make it possible for African companies to manufacture mRNA vaccines in 9-12 months.
Afrigen's facility will have the capacity to produce up to 10,000 vials a day of COVID-19 vaccines and it has partnered with local manufacturer Biovac which can produce 30 to 50 million doses a year to distribute across Africa.
Research partners include South African universities and local genomics surveillance lab KRISP.
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva